Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized, double-blind study

Jadwiga Szlachcic, W. Dallas Hall, Julio F. Tubau, Vivian Porter, Carol Vollmer, Gary Wollam, Alan Hirsch, Barry Massie

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Hypertensive patients with left ventricular hypertrophy (LVH) have increased cardiovascular morbidity and mortality. Experimental studies indicate the importance of both the alpha and beta components of the adrenergic nervous system in the development and reversal of LVH. Therefore labetalol (L), a combined alpha and beta blocker, and propranolol (P), a nonselective beta blocker, were evaluated in a randomized, double-blind study of 35 hypertensive patients with echocardiographic evidence of LVH. Following 2 weeks of placebo, L or P was titrated as needed and tolerated to maximum total daily doses of 1600 mg and 640 mg, respectively. A thiazide diuretic was added if necessary for blood pressure control. M-mode echocardiograms were performed at baseline and after 1, 3, 6 and 12 months of blood pressure control. The echocardiograms were read independently by two blinded observers for end-diastolic dimension and wall thicknesses, and left ventricular mass. Fractional shortening, cardiac output, and peripheral vascular resistance were derived using standard formulas. Both drugs reduced blood pressure significantly and comparably. Significant changes in the echocardiographic measurements were observed as early as 1 month and usually persisted throughout the study. Both drugs decreased posterior wall thickness; however, only the decrease in propranolol group achieved statistical significance. Septal wall thickness was reduced by L at 3 and 12 months. End-diastolic dimension increased significantly in the L-treated group at 3, 6, and 12 months of therapy, whereas P had no effect on this measurement. As a consequence, the calculated left ventricular mass index was reduced by P throughout the study, but remained essentially unchanged by L until the twelfth month. Neither drug adversely affected fractional shortening. Cardiac output was significantly reduced by P, but unchanged by L, despite similar effects on heart rate by both drugs. Thus, despite their similar effects on blood pressure, L and P had different effects on cardiac morphology, which may reflect varying responses to alpha-and beta-adrenergic blockade.

Original languageEnglish (US)
Pages (from-to)427-433
Number of pages7
JournalCardiovascular Drugs and Therapy
Issue number2
StatePublished - Mar 1990


  • Left ventricular hypertrophy
  • adrenergic blockers
  • echocardiography
  • labetalol
  • propranolol


Dive into the research topics of 'Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized, double-blind study'. Together they form a unique fingerprint.

Cite this